Biogen key posters presented at ECTRIMS 2019

At ECTRIMS 2019, Biogen presented a number of posters showing the latest data on several current hot topics in the field of MS. These are our highlights:

Disease Control Beyond NEDA: The Value of Nonclinical Disease Activity Measures to Determine Treatment Response to Natalizumab

 

Analysis of the AFFIRM trial revealed that MRI activity, sNfL, and relapses had the strongest association with natalizumab treatment over 2 years.

A Quantitative View of MS Disease Course

 

Standardisation of MRI acquisition and analysis enables high-quality MRI-based metrics and systematic learning from routine patient care.

ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis;
MRI: Magnetic Resonance Imaging;
NEDA: No Evidence of Disease Activity;
sNfL: Serum Neurofilament Light Chain.

Biogen-28276.
Date of preparation: October 2019.